Duloxetine
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Major Depression
Conditions
Major Depression, Irritable Bowel Syndrome
Trial Timeline
Dec 1, 2008 → Dec 1, 2014
NCT ID
NCT01754493About Duloxetine
Duloxetine is a approved stage product being developed by Eli Lilly for Major Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT01754493. Target conditions include Major Depression, Irritable Bowel Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Major Depression were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391221 | Approved | UNKNOWN |
| NCT01363284 | Pre-clinical | Completed |
| NCT01089621 | Approved | Withdrawn |
| NCT01051466 | Approved | Completed |
| NCT00989157 | Phase 3 | Completed |
| NCT01074151 | Pre-clinical | Completed |
| NCT00889369 | Approved | UNKNOWN |
| NCT01754493 | Approved | Completed |
| NCT01028352 | Pre-clinical | Completed |
| NCT00696774 | Approved | Completed |
| NCT00532480 | Approved | Completed |
| NCT00529789 | Phase 2 | Completed |
| NCT00696293 | Approved | Completed |
| NCT00517985 | Approved | Completed |
| NCT00398632 | Approved | Terminated |
| NCT00401258 | Approved | Completed |
| NCT00438971 | Approved | Completed |
| NCT00531895 | Approved | Completed |
| NCT00322621 | Approved | Completed |
| NCT01035073 | Approved | Completed |
Competing Products
20 competing products in Major Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 29 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 29 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 40 |